Literature DB >> 11159919

Defect in N-glycosylation of proteins is tissue-dependent in congenital disorders of glycosylation Ia.

T Dupré1, A Barnier, P de Lonlay, V Cormier-Daire, G Durand, P Codogno, N Seta.   

Abstract

The biochemical hallmark of Congenital Disorders of Glycosylation (CDG) including type Ia is a defective N-glycosylation of serum glycoproteins. Hypoglycosylated forms of alpha1-antitrypsin have been detected by Western blot in serum from CDG Ia patients. In contrast we were not able to detect hypoglycosylation in alpha1-antitrypsin synthesized by fibroblasts, keratinocytes, enterocytes, and leukocytes. Similarly no hypoglycosylation was detectable in a membrane-associated N-linked glycoprotein, the facilitative glucose transporter GLUT-1 and also in serum immunoglobulin G isolated from sera of CDG Ia patients. We conclude that the phenotypic expression of CDG Ia is tissue-dependent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11159919     DOI: 10.1093/glycob/10.12.1277

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  10 in total

1.  Abnormal lysosomal inclusions in liver hepatocytes but not in fibroblasts in congenital disorders of glycosylation (CDG).

Authors:  S Grünewald; R De Vos; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

2.  Stabilization of hypoglycosylation in a patient with congenital disorder of glycosylation type Ia.

Authors:  S H Hahn; S J Minnich; J F O'Brien
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Improvement of CDG diagnosis by combined examination of several glycoproteins.

Authors:  J Fang; V Peters; B Assmann; C Körner; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: implications for extracellular glucose and intracellular mannose 6-phosphate.

Authors:  Ningguo Gao; Jie Shang; Mark A Lehrman
Journal:  J Biol Chem       Date:  2005-02-11       Impact factor: 5.157

Review 5.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 6.  Immunological aspects of congenital disorders of glycosylation (CDG): a review.

Authors:  Maria Monticelli; Tiago Ferro; Jaak Jaeken; Vanessa Dos Reis Ferreira; Paula A Videira
Journal:  J Inherit Metab Dis       Date:  2016-07-08       Impact factor: 4.750

7.  Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity.

Authors:  Aurélie Cazet; Jonathan Charest; Daniel C Bennett; Cecilia Lopez Sambrooks; Joseph N Contessa
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

8.  Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).

Authors:  Christina T Thiesler; Samanta Cajic; Dirk Hoffmann; Christian Thiel; Laura van Diepen; René Hennig; Malte Sgodda; Robert Weiβmann; Udo Reichl; Doris Steinemann; Ulf Diekmann; Nicolas M B Huber; Astrid Oberbeck; Tobias Cantz; Andreas W Kuss; Christian Körner; Axel Schambach; Erdmann Rapp; Falk F R Buettner
Journal:  Mol Cell Proteomics       Date:  2016-01-19       Impact factor: 5.911

9.  Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease.

Authors:  Andreas J Hülsmeier; Micha Tobler; Patricie Burda; Thierry Hennet
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

10.  A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.

Authors:  Abigail Cline; Ningguo Gao; Heather Flanagan-Steet; Vandana Sharma; Sabrina Rosa; Roberto Sonon; Parastoo Azadi; Kirsten C Sadler; Hudson H Freeze; Mark A Lehrman; Richard Steet
Journal:  Mol Biol Cell       Date:  2012-09-05       Impact factor: 4.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.